Podcast: Key takeaways from EASD 2026 on where GLP-1s are headed
The world of diabetes and obesity research has exploded in recent years with the blockbuster success of glucagon-like peptide (GLP)-1…
Metabolic Disorders
-
-
GLP-1RA non-responders: tackling a hidden challenge behind the obesity epidemic
In recent years, the notoriety and uptake of incretin-based therapies such as glucagon-like peptide-1 receptor agonists (GLP-1RAs) has skyrocketed, with…
-
Varda pockets $251m to back space-based pharma processing mission
Varda Space Industries has banked $251m in a Series D financing to scale its in-space pharmaceutical processing operations, as the…
-
EASD 2026: Tirzepatide outperforms semaglutide in real-world type 2 diabetes analysis
This year at the European Association for the Study of Diabetes (EASD) Annual Meeting, real-world data were presented comparing Eli…
-
EASD 2026: Orforglipron shows an efficacy edge over oral semaglutide in T2D
This year at the European Association for the Study of Diabetes (EASD) Annual Meeting, an indirect treatment comparison evaluated Eli…
-
Sanofi aims for Nexviazyme approval in younger Pompe disease patients
Sanofi’s Nexviazyme (avalglucosidase alfa) could be set for approval in younger children with Pompe disease after the Phase III Baby-COMET…
-
ADA26: retatrutide delivers unprecedented weight loss in Phase III TRIUMPH-1
On 6 June, at the 86th Scientific Sessions of the American Diabetes Association (ADA) in New Orleans, Louisiana, findings from…
-
ECRD 2026: Europe’s rare disease bottleneck is funding rather than science
Rare disease R&D investment is outpacing the broader biotech market, while the pipeline of innovative therapies continues to deepen. With…
-
ECO 2026: tirzepatide shows potential for T1D treatment
During the 2026 European Congress on Obesity (ECO) in Istanbul, a meta-analysis was presented analysing the use of tirzepatide, a…
-
ECO 2026: gut hormone signals differ in T1D with obesity
At the 2026 European Congress on Obesity (ECO) in Istanbul, researchers presented a small observational study assessing fasting peptide YY…
